Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a cash flow conversion efficiency ratio of -0.084x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.61 Million) by net assets ($102.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sagimet Biosciences Inc. Series A Common (SGMT) balance sheet quality index to measure how much of total assets are equity-financed.
Sagimet Biosciences Inc. Series A Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore investment intensity of Sagimet Biosciences Inc. Series A Common to see how much of total assets are deployed in long-term investments.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Topkey Corp
TW:4536
|
0.026x |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
0.068x |
|
Chengdu KSW Technologies Co. Ltd. A
SHG:688283
|
0.038x |
|
Sprout Social Inc
NASDAQ:SPT
|
0.117x |
|
Clientele
JSE:CLI
|
-0.059x |
|
Nanjing Well Pharmaceutical Co Ltd
SHG:603351
|
0.039x |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
0.016x |
|
Edom Technology Co Ltd
TW:3048
|
-0.709x |
Annual Cash Flow Conversion Efficiency for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Sagimet Biosciences Inc. Series A Common stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.38 Million | $-45.65 Million | -0.410x | -50.48% |
| 2024-12-31 | $155.81 Million | $-42.44 Million | -0.272x | -4.36% |
| 2023-12-31 | $91.06 Million | $-23.77 Million | -0.261x | -299.22% |
| 2022-12-31 | $-186.95 Million | $-24.49 Million | 0.131x | -4.51% |
| 2021-12-31 | $-158.26 Million | $-21.71 Million | 0.137x | +79.00% |
| 2020-12-31 | $-135.91 Million | $-10.42 Million | 0.077x | -8.98% |
| 2019-12-31 | $-125.31 Million | $-10.55 Million | 0.084x | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfun… Read more